Tetraphase Pharmaceuticals, Inc. (TTPH) Shares Down 8%
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) dropped 8% during trading on Monday . The stock traded as low as $6.32 and last traded at $6.33. Approximately 674,347 shares changed hands during trading, a decline of 7% from the average daily volume of 723,146 shares. The stock had previously closed at $6.88.
A number of brokerages have recently issued reports on TTPH. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price target on the stock. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Saturday, September 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the company earned ($0.58) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% on a year-over-year basis. research analysts anticipate that Tetraphase Pharmaceuticals, Inc. will post -2.88 earnings per share for the current year.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares in the company, valued at approximately $52,762.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in TTPH. JPMorgan Chase & Co. bought a new stake in Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $7,915,000. Canada Pension Plan Investment Board increased its position in shares of Tetraphase Pharmaceuticals by 54.4% during the 3rd quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after purchasing an additional 900,000 shares during the last quarter. Numeric Investors LLC increased its position in shares of Tetraphase Pharmaceuticals by 1,363.3% during the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at approximately $4,516,000. Finally, Dimensional Fund Advisors LP grew its position in Tetraphase Pharmaceuticals by 73.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after acquiring an additional 466,955 shares during the last quarter. 47.40% of the stock is currently owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.